


The largest prospective NIPT study



Scan here to learn more
about **Panorama™**

PATIENTS

20,000+
enrolled

SITES

21
global centers

OUTCOMES

100%
of patients included in analysis
had genetic confirmation

Study Objective

To measure the performance of single nucleotide polymorphism (SNP)-based, non-invasive prenatal testing (NIPT) in a prospective study for trisomies 21, 18 and 13; monosomy X; 22q11.2 deletion syndrome; and microdeletion panel (1p36, Cri-du-chat, Prader-Willi and Angelman syndromes) in a large cohort of pregnant people clinically receiving NIPT.

Certified Lab




Panorama™
Next-generation NIPT



Aneuploidy detection

Demonstrated high performance in singleton pregnancies¹


- Included a large cohort of average-risk pregnancies¹
- Panorama™'s high sensitivity and specificity were maintained in real-world clinical practice



22Q11.2 deletion detection

SMART study showed that 22q11.2 deletion syndrome had a higher than expected prevalence.



This is comparable to other conditions broadly recommended for routine screening, by professional medical guidelines, such as cystic fibrosis^{4, 25-29}



SMART data suggests that the incidence of small 22q11.2 deletions is much higher than expected.

Panorama™ was able to detect all cases of the most common (2.5-3Mb)¹ 22q11.2 deletion, and 82% of all 22q11.2 deletions (0.5Mb+)

Chromosome 22*



*Not to scale

**FISH or BACS-on-beads used for confirmatory testing; deletion spans A-B region at a minimum

Panorama™ delivered higher sensitivity for 22q11.2 deletion syndrome, enabling accurate and early detection

Panorama™ was validated in SMART with high accuracy and high positive predictive value (PPV) for 22q11.2 deletions.^{1,4,5}

>99.9%
sensitivity

Most common deletion size (2.5 Mb+)

Mb = Megabase pair

83%
sensitivity


Full and nested deletions (0.5 Mb+)

53%
PPV

Full and nested deletions (0.5 Mb+)

Importance of early, accurate 22q11.2 deletion screening¹¹⁻¹⁴

Perinatal interventions can improve quality of life of individuals affected by 22q11.2 deletion³⁰⁻³⁴



Early intervention can reduce the severity of these conditions associated with 22q11.2 deletion syndrome:¹¹⁻¹⁴


- Delivery at tertiary center
- Calcium-level monitoring at birth
- Delayed live-vaccine administration
- Palatal evaluation for potential feeding and breathing issues

Why choose Panorama™ NIPT?

TESTS
3 MILLION+
performed across 90 countries

PATIENTS
1.3 MILLION+
studied

PUBLICATIONS
25+



Patient support every step of the way

Services included with Panorama™ NIPT:

Patient Education

Patient-friendly materials available on our website and patient service centres in English and French.

Convenient Sample Collection and Testing Within Canada

Panorama™ NIPT samples can be collected at any LifeLabs patient service centre or national affiliates and testing is performed within Canada.

Genetic Counselling Support

Certified Canadian genetic counsellors are available to healthcare providers and patients to answer any questions about the test or results at **Ask.Genetics@LifeLabs.com** or **1-844-363-4357**. In addition, our genetic counsellors proactively contact healthcare providers about abnormal results to provide clear next steps for their patients. Services are available from 8am-7pm EST in both English and French.

1. Dar et al. Am J Obstet Gynecol. Published online January 24, 2022. doi:10.1016/j.ajog.2022.01.019 | 2. Pergament et al. Obstet Gynecol. 2014 Aug; 124(2 Pt 1):210-8. | 3. Ryan et al. Fetal Diagn Ther. 2016; 40(3):219-23. | 4. Dar et al. Am J Obstet Gynecol. Published online January 13, 2022. doi:10.1016/j.ajog.2022.01.002 | 5. Norton et al. Perinatal and genetic outcomes associated with no call cfDNA results in 18,497 pregnancies; SFMS's 40th Annual Pregnancy Meeting 2021. | 6. Norwitz et al. J Clin Med. 2019 Jun; 8:937. | 7. Hedriana et al. Prenat Diagn. 2020 Jan; 40(2):179-84. | 8. Nicolaides et al. Fetal Diagn Ther. 2014; 35(3):212-7. | 9. DiNonno et al. J Clin Med. 2019 Aug; 8(9):1311. | 10. Internal data, Natera. | 11. Stokowski et al. Prenat Diagn. 2015 Dec; 35(12):1243-6. | 12. Jones et al. Ultrasound Obstet Gynecol. 2018 Feb; 51(2):275-6. | 13. Hooks et al. Prenat Diagn. 2014 May; 34(5):496-9. | 14. Schmid et al. Fetal Diagn Ther. 2018; 44(4):299-304. | 15. Palomaki et al. Genet Med. 2011 Nov; 13(11):913-20. | 16. Palomaki et al. Genet Med. 2012 Mar; 14(3):296-305. | 17. Mazloom et al. Prenat Diagn. 2013 Jun; 33(6):591-7. | 18. Tynan et al. SMFM 37th Annual Pregnancy Meeting 2017. | 19. Sehner et al. Clin Chem. 2011 Jun; 57(7):1042-9. | 20. Bianchi et al. Obstet Gynecol. 2012 May; 119(5):890-901. | 21. Bianchi et al. N Engl J Med. 2014 Feb; 370(9):799-808. | 22. Verinata Health. Analytical validation of the Verifi prenatal test, 2012. | 23. The commercial protocol is not validated. Illumina marketing materials cite Srinivasan et al. Am J Hum Genet. 2013 Feb; 92(2):167-76, which does not match the number of reads used in commercial testing. | 24. Dar and Norton. Am J Obstet Gynecol. 2022. Epub prior to publication. doi: https://doi.org/10.1016/j.ajog.2022.01.036. | 25. Maternal age-related risk for common fetal trisomies across pregnancy. UpToDate. Accessed January 20, 2022. https://www.uptodate.com/contents/image?imageKey=OBGYN%2F75423 | 26. Martin et al. Natl Vital Stat Rep. 2021 Apr; 70(2):1-51. doi: https://dx.doi.org/10.15620/cdc:100472. | 27. Hamosh et al. J Pediatr. 1998 Feb; 132(2):255-9. | 28. O'Sullivan, Freedman. Lancet. 2009 May; 373(9678):1891-904. | 29. Prior et al. Spinal muscular atrophy. In: Adam et al, eds. GeneReviews. University of Washington; 2000. | 30. Bassett et al. J Pediatr. 2011 Aug; 159(2):332-9.e1. | 31. Cheung et al. Genet Med. 2014 Jan; 16(1):40-4. | 32. Grand et al. Am J Med Genet A. 2018 Oct; 176(10):2167-71. | 33. Palmer et al. Am J Med Genet A. 2018 Apr; 176(4):936-44. | 34. McDonald-McGinn et al. 22q11.2 Deletion Syndrome. In: Adam et al, editors. GeneReviews. University of Washington, 1993- 2022.

LifeLabsGenetics.com/Panorama

LifeLabs LP. © LifeLabs 2022. Natera and Panorama are trademarks of Natera Inc., used with permission. LifeLabs is a registered trademark and LifeLabs Genetics is a trademark of LifeLabs LP. LifeLabs Genetics is an authorized laboratory of Natera's Panorama test in Canada. The content has not been reviewed by nor endorsed by Natera, Inc. LifeLabs Genetics is solely responsible for maintaining the content according to Natera partnership guidelines as well as all legal and regulatory requirements in Canada. CAP accredited, ISO 13485 and CLIA certified. © 2022 Natera, Inc. All Rights Reserved.

LifeLabs
GENETICS

LifeLabs Genetics | Panorama SMART Detail Aid VER 6 | OCT 2022